4D Molecular Therapeutics announced its Q1 2026 financial results, reporting a net loss of $68.8 million driven by increased R&D expenses for Phase 3 trials of its lead product 4D-150 targeting wet age-related macular degeneration (AMD). The company completed enrollment for the 4FRONT-1 Phase 3 trial and expects topline data in the first half of 2027, with further trial milestones planned through 2027. It holds $458 million in cash and equivalents, sufficient to fund operations into the second half of 2028. Upcoming milestones include data presentations for other trials and initiation of a global Phase 3 trial for diabetic macular edema.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
